|
|
Blood, 1 March 2005, Vol. 105, No. 5, pp. 2135-2137.
Prepublished online as a Blood First Edition Paper on November 2, 2004; DOI 10.1182/blood-2004-07-2573.
 Previous Article | Next Article 
Submitted July 8, 2004
Accepted October 25, 2004
Deregulated expression of the Myc cellular oncogene drives development of mouse 'Burkitt-like' lymphomas from naive B cells
Delin Zhu*, Chen F Qi, Herbert C Morse III, Siegfried Janz, and Freda K Stevenson
Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton, United Kingdom
Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Laboratory of Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
* Corresponding author; email: D.Zhu{at}soton.ac.uk.
Chromosomal translocations juxtaposing Ig and MYC genes are the hallmarks of human Burkitt lymphoma (BL) with deregulated MYC expression being a critical factor in pathogenesis. By inserting an intact mouse Myc gene into the mouse genome, proximal to the Ig enhancer Emu, the effect of a precise mimic of the major t(8;14) translocation of human endemic BL (eBL) could be investigated. Knock-in mice developed IgM-positive B-cell tumors, with most being typical of eBL by histology and immunophenotype including expression of the germinal center (GC)-associated protein, BCL6. Unlike eBL, however, analysis of Ig VH sequences revealed no significant level of somatic mutation. Thus, constitutive expression of Myc in the knock-in mice is apparently able to induce "Burkitt-like" lymphomas before antigen stimulation and formation of a GC. In contrast, human eBL development occurs in a GC or post-GC site with a likely contribution to pathogenesis from EBV and other epigenetic factors.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Mori, R. E. Rempel, J. T. Chang, G. Yao, A. S. Lagoo, A. Potti, A. Bild, and J. R. Nevins
Utilization of Pathway Signatures to Reveal Distinct Types of B Lymphoma in the E{micro}-myc Model and Human Diffuse Large B-Cell Lymphoma
Cancer Res.,
October 15, 2008;
68(20):
8525 - 8534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. J. Guikema, E. Schuuring, and P. M. Kluin
Structure and Consequences of IGH Switch Breakpoints in Burkitt Lymphoma
J Natl Cancer Inst Monographs,
July 1, 2008;
2008(39):
32 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Truffinet, E. Pinaud, N. Cogne, B. Petit, L. Guglielmi, M. Cogne, and Y. Denizot
The 3' IgH Locus Control Region Is Sufficient to Deregulate a c-myc Transgene and Promote Mature B Cell Malignancies with a Predominant Burkitt-Like Phenotype
J. Immunol.,
November 1, 2007;
179(9):
6033 - 6042.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kotani, N. Kakazu, T. Tsuruyama, I.-m. Okazaki, M. Muramatsu, K. Kinoshita, H. Nagaoka, D. Yabe, and T. Honjo
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice
PNAS,
January 30, 2007;
104(5):
1616 - 1620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Kelly and A. B. Rickinson
Burkitt Lymphoma: Revisiting the Pathogenesis of a Virus-Associated Malignancy
Hematology,
January 1, 2007;
2007(1):
277 - 284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Stebbing, S. Mandalia, C. Palmieri, M. Nelson, B. Gazzard, and M. Bower
Burkitt's Lymphoma and Previous AIDS-Defining Illnesses Are Not Prognostic Factors in AIDS-Related Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
November 20, 2005;
23(33):
8538 - 8540.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bellan, S. Lazzi, M. Hummel, N. Palummo, M. de Santi, T. Amato, J. Nyagol, E. Sabattini, T. Lazure, S. A. Pileri, et al.
Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas
Blood,
August 1, 2005;
106(3):
1031 - 1036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
